[HTML][HTML] Investigation of stabilized amorphous solid dispersions to improve oral olaparib absorption
T Yun, S Lee, S Yun, D Cho, K Bang, K Kim - Pharmaceutics, 2024 - mdpi.com
In this study, we investigated the formulation of stable solid dispersions to enhance the
bioavailability of olaparib (OLA), a therapeutic agent for ovarian cancer and breast cancer …
bioavailability of olaparib (OLA), a therapeutic agent for ovarian cancer and breast cancer …
Development of gefitinib-loaded solid lipid nanoparticles for the treatment of breast cancer: physicochemical evaluation, stability, and anticancer activity in breast …
In the current study, the toxic effects of gefitinib-loaded solid lipid nanoparticles (GFT-loaded
SLNs) upon human breast cancer cell lines (MCF-7) were investigated. GFT-loaded SLNs …
SLNs) upon human breast cancer cell lines (MCF-7) were investigated. GFT-loaded SLNs …
Improving the physicochemical and pharmacokinetic properties of olaparib through cocrystallization strategy
XL Dai, BW Pang, WT Lv, JF Zhen, L Gao, CW Li… - International Journal of …, 2023 - Elsevier
Olaparib (OLA) is the first PARP inhibitor worldwide used for the treatment of ovarian cancer.
However, the oral absorption of OLA is extremely limited by its poor solubility. Herein …
However, the oral absorption of OLA is extremely limited by its poor solubility. Herein …
Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal …
Eluxadoline (ELD), a recently approved drug, exhibits potential therapeutic effects in the
management and treatment of IBS-D. However, its applications have been limited due to …
management and treatment of IBS-D. However, its applications have been limited due to …
Development and characterization of ibrutinib-loaded ethylcellulose-based nanosponges: Cytotoxicity assay against MCF-7 cell lines
Ibrutinib (ITB) is a specific and novel irreversible inhibitor of Bruton's tyrosine kinase
enzyme, for which reason it exhibits potential chemotherapeutic effects against a few types …
enzyme, for which reason it exhibits potential chemotherapeutic effects against a few types …
Effect of Polyamorphism on the Morphology, Dissolution, and Stability of Olaparib
L Gao, XL Dai, SY Li, NA Vasilev… - Crystal Growth & …, 2024 - ACS Publications
Olaparib (OLA) is an insoluble targeting antitumor drug for the treatment of ovarian cancer.
Herein, polyamorphism of OLA was systematically studied aiming to improve its solubility …
Herein, polyamorphism of OLA was systematically studied aiming to improve its solubility …
Evaluation of Anticancer Efficacy of D-α-Tocopheryl Polyethylene-Glycol Succinate and Soluplus® Mixed Micelles Loaded with Olaparib and Rapamycin Against …
YB Shin, JY Choi, MS Yoon, MK Yoo… - International Journal …, 2024 - Taylor & Francis
Purpose Ovarian cancer has the highest mortality rate and lowest survival rate among
female reproductive system malignancies. There are treatment options of surgery and …
female reproductive system malignancies. There are treatment options of surgery and …
Solid Dispersions of Gefitinib with D-α-Tocopherol Polyethylene Glycol-1000 Succinate and 2-Hydroxypropyl β-Cyclodextrin Complex Improved Their Solubility …
This study focuses on the development and characterization of solid dispersions (SDs) of
Gefitinib (GEF) to improve its aqueous solubility and therapeutic activity against lung cancer …
Gefitinib (GEF) to improve its aqueous solubility and therapeutic activity against lung cancer …
[HTML][HTML] A Quaternary Solid Dispersion System for Improving the Solubility of Olaparib
TH Yun, JG Lee, KH Bang, JH Cho, KS Kim - Solids, 2025 - mdpi.com
To improve the low solubility of poorly water soluble olaparib, in the following study, we
prepared olaparib-loaded quaternary solid dispersions with hypromellose, Tween 20 or …
prepared olaparib-loaded quaternary solid dispersions with hypromellose, Tween 20 or …